These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34972781)

  • 1. Infantile mediastinal neuroblastoma presenting as an oncologic emergency: usefulness of serum-based
    Suematsu M; Yagyu S; Hosoi H; Iehara T
    BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34972781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patients.
    Iehara T; Yagyu S; Gotoh T; Ouchi K; Yoshida H; Miyachi M; Kikuchi K; Sugimoto T; Hosoi H
    Jpn J Clin Oncol; 2019 Aug; 49(8):743-748. PubMed ID: 31053863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
    Yagyu S; Iehara T; Tanaka S; Gotoh T; Misawa-Furihata A; Sugimoto T; London WB; Hogarty MD; Teramukai S; Nakagawara A; Hiyama E; Maris JM; Hosoi H
    PLoS One; 2016; 11(8):e0161039. PubMed ID: 27513929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
    Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
    Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
    J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
    Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
    Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
    Marrano P; Irwin MS; Thorner PS
    Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.
    Berbegall AP; Bogen D; Pötschger U; Beiske K; Bown N; Combaret V; Defferrari R; Jeison M; Mazzocco K; Varesio L; Vicha A; Ash S; Castel V; Coze C; Ladenstein R; Owens C; Papadakis V; Ruud E; Amann G; Sementa AR; Navarro S; Ambros PF; Noguera R; Ambros IM
    Br J Cancer; 2018 May; 118(11):1502-1512. PubMed ID: 29755120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Bhardwaj N; Rohilla M; Trehan A; Bansal D; Kakkar N; Srinivasan R
    J Clin Pathol; 2023 Sep; 76(9):599-605. PubMed ID: 35414524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma.
    Yagyu S; Gotoh T; Iehara T; Miyachi M; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tamura S; Tsuchiya K; Imamura T; Misawa-Furihata A; Sugimoto T; Sawada T; Hosoi H
    Clin Cancer Res; 2008 Nov; 14(21):7011-9. PubMed ID: 18980997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
    Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
    J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
    Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group.
    Kawano A; Hazard FK; Chiu B; Naranjo A; LaBarre B; London WB; Hogarty MD; Cohn SL; Maris JM; Park JR; Gastier-Foster JM; Ikegaki N; Shimada H
    Am J Surg Pathol; 2021 Aug; 45(8):1075-1081. PubMed ID: 33739795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting amplification of
    Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
    Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation Between
    Santiago T; Tarek N; Boulos F; Hayes C; Jeha S; Raimondi S; Rodriguez-Galindo C
    J Glob Oncol; 2019 Jul; 5():1-7. PubMed ID: 31365300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
    Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in
    Zhao M; Gu W; Liu F; Yu L; Shu Y; Liu L; Hu J; Liu Y; Tang H; Mao J
    Pediatr Dev Pathol; 2023; 26(2):124-132. PubMed ID: 36775958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
    Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
    Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.